Evidence map›Paper›PMID 21493862›Full record

ArticleScience (New York, N.Y.)2011

Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice.

Tammy M Holm, Jennifer P Habashi, Jefferson J Doyle, Djahida Bedja, YiChun Chen, Christel van Erp, Mark E Lindsay, David Kim, Florian Schoenhoff, Ronald D Cohn and 6 more

Open access · greenAbstract read
In one paragraph

Article in Science (New York, N.Y.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 276 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
276citing papers in PubMed, 1 pooled it
32.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

276 citing papers in PubMed, 1 synthesis or guideline pooled it, 464 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

216 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Tammy M HolmHoward Hughes Medical Institute and Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Jennifer P Habashi
Jefferson J Doyle
Djahida Bedja
YiChun Chen
Christel van Erp
Mark E Lindsay
David Kim
Florian Schoenhoff
Ronald D Cohn
Bart L Loeys
Craig J Thomas
Samarjit Patnaik
Juan J Marugan
Daniel P Judge
Harry C Dietz
Johns Hopkins University · USNational Institutes of Health · USJohns Hopkins Medicine · US

Funding

NIH Chemical Genomics CenterZIBHG200319 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI AUSTIN, CHRISTOPHER P · 2010 to 2011
$55.9M
PROJECT 4: Exploration of Therapeutic Strategies in MarP01AR049698 · NIAMS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI RAMIREZ, FRANCESCO B · 2004 to 2014
$13.9M
Predoctoral Training Program in Human GeneticsT32GM007814 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI VALLE, DAVID · 1985 to 2021
$10.6M
MOLECULAR BIOLOGY OF THE MARFAN SYNDROMER01AR041135 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI DIETZ, HARRY C., III · 1992 to 2016
$5.2M
Howard Hughes Medical InstituteIntramural NIH HHSNIAMS NIH HHS P01 AR049698NIAMS NIH HHS R01 AR041135NIGMS NIH HHS T32 GM007814
6 · The paper itself

Abstract

Transforming growth factor-β (TGFβ) signaling drives aneurysm progression in multiple disorders, including Marfan syndrome (MFS), and therapies that inhibit this signaling cascade are in clinical trials. TGFβ can stimulate multiple intracellular signaling pathways, but it is unclear which of these pathways drives aortic disease and, when inhibited, which result in disease amelioration. Here we show that extracellular signal-regulated kinase (ERK) 1 and 2 and Smad2 are activated in a mouse model of MFS, and both are inhibited by therapies directed against TGFβ. Whereas selective inhibition of ERK1/2 activation ameliorated aortic growth, Smad4 deficiency exacerbated aortic disease and caused premature death in MFS mice. Smad4-deficient MFS mice uniquely showed activation of Jun N-terminal kinase-1 (JNK1), and a JNK antagonist ameliorated aortic growth in MFS mice that lacked or retained full Smad4 expression. Thus, noncanonical (Smad-independent) TGFβ signaling is a prominent driver of aortic disease in MFS mice, and inhibition of the ERK1/2 or JNK1 pathways is a potential therapeutic strategy for the disease.

Indexed as

MAP Kinase Signaling SystemAnimalsAnthracenesAortaAortic AneurysmDiphenylamineDisease Models, AnimalDisease ProgressionEnzyme ActivationLosartanMarfan SyndromeMiceMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Mitogen-Activated Protein Kinase 8Protein Kinase InhibitorsAnthracenesDiphenylamineLosartanMapk1 protein, mouseMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Mitogen-Activated Protein Kinase 8N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamideProtein Kinase InhibitorspyrazolanthroneSmad2 ProteinSmad2 protein, mouseSmad4 ProteinSmad4 protein, mouseSulfonamidesTransforming Growth Factor beta

Identifiers

PMID21493862
PMCPMC3111087
OpenAlexW2023431960

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.